C16-PAF (Synonyms: PAF (C16))

Name: C16-PAF
Brand: MedChemExpress
SKU: HY-108635
Rating: 5.0 (40 reviews)

Cat. No.: HY-108635 Purity: 99.85%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

For research use only. We do not sell to patients.

CAS No. : 74389-68-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 40 publication(s) in Google Scholar

Other Forms of C16-PAF:

C16-PAF (Standard) Get quote

40 Publications Citing Use of MCE C16-PAF

Cell Proliferation/Viability Assay

: C16-PAF purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 17;16(1):1715. [Abstract]; WB was performed to measure the protein levels of pERK1/2 and ERK1/2. C16-PAF (100 nM) facilitates the activation of the MAPK pathway and increases EV-D68 78 replication in CXCL8-silenced cells.

: C16-PAF purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 17;16(1):1715. [Abstract]; C16-PAF (100 nM) facilitates the activation of the MAPK pathway and increases EV-D68 replication in CXCL8-silenced cells.

: C16-PAF purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Aug:144:156949. [Abstract]; Western blot analysis of p-ERK1/2, p-MEK, HK2, PKM2, and LDHA levels in 143B and U2R cells treated with C16-PAF (1 µM).

: C16-PAF purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 1:235:231-247. [Abstract]; In SUM159 cells treated with ERK agonist (1 μM C16-PAF) in combination with indicated concentrations of RES for 12 h, the protein levels of p-ERK1/2, ERK1/2, p-NEDD4L, NEDD4L, p-SGK1, SGK1 and GPX4 were measured by western blotting assays.

: C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]; LN229 and U251 cells were treated with 1.25 µM Mito-LND and/or 20 µM C16-PAF for 36 h, then cell viabilities were evaluated by CCK-8 assay.

: C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]; The effects of Mito-LND and/or C16-PAF (20 µM) treatment on the levels of p-ERK1/2, p-p90RSK, Bcl-2 and Bax in LN229 and U251 cells were assessed by western blot analysis.

: C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]; The effects of Mito-LND and/or C16-PAF (20 µM) treatment on the mitochondrial membrane potential, Scale bar: 40 μm.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All MEK Isoform Specific Products:

View All Isoforms

MEK1 MEK2 MEK5 MEK MAP2K4/MEK4 MAP2K7/MEK7

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[4]^[5]

Human Endogenous Metabolite

ERK

MEK

In Vitro

C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR^/ but not PAFR^+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR^/ cells infected with EGFP alone^[1].
C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR^/ neurons^[1].
C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor^[2]^[3].
C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Cerebellar granule neurons (CGNs) from PAFR^−/− and PAFR^+/+ mice
Concentration:	0.5-1.5 μM
Incubation Time:	24 hours
Result:	Elicited significant concentration-dependent neuronal loss in PAFR^−/− but not PAFR^+/+ cultures in serum-free media.

Western Blot Analysis^[1]

Cell Line:	CGNs
Concentration:	1 μM
Incubation Time:	24 hours
Result:	Activated caspase 7 but not caspase 3 in PAFR^−/− neurons.

Molecular Weight

523.68

Formula

C₂₆H₅₄NO₇P

CAS No.

74389-68-7

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (190.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9096 mL	9.5478 mL	19.0956 mL
5 mM	0.3819 mL	1.9096 mL	3.8191 mL
10 mM	0.1910 mL	0.9548 mL	1.9096 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.86%

Select Batch:

Data Sheet (273 KB) SDS (252 KB)

COA (240 KB) HNMR (266 KB) RP-HPLC (246 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8. [Content Brief]

[2]. Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269(3):2307-15. [Content Brief]

[3]. Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903. [Content Brief]

[4]. Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562. [Content Brief]

[5]. Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9096 mL	9.5478 mL	19.0956 mL	47.7391 mL
	5 mM	0.3819 mL	1.9096 mL	3.8191 mL	9.5478 mL
	10 mM	0.1910 mL	0.9548 mL	1.9096 mL	4.7739 mL
	15 mM	0.1273 mL	0.6365 mL	1.2730 mL	3.1826 mL
	20 mM	0.0955 mL	0.4774 mL	0.9548 mL	2.3870 mL
	25 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9096 mL
	30 mM	0.0637 mL	0.3183 mL	0.6365 mL	1.5913 mL
	40 mM	0.0477 mL	0.2387 mL	0.4774 mL	1.1935 mL
	50 mM	0.0382 mL	0.1910 mL	0.3819 mL	0.9548 mL
	60 mM	0.0318 mL	0.1591 mL	0.3183 mL	0.7957 mL
	80 mM	0.0239 mL	0.1193 mL	0.2387 mL	0.5967 mL
	100 mM	0.0191 mL	0.0955 mL	0.1910 mL	0.4774 mL

C16-PAF Related Classifications

Inflammation/Immunology Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

C16-PAF (Synonyms: PAF (C16))

Customer Review

Other Forms of C16-PAF:

C16-PAF Related Antibodies

40 Publications Citing Use of MCE C16-PAF

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All MEK Isoform Specific Products:

View All ERK Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

C16-PAF Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

C16-PAF Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report